StreetAlpha.app
Home › Stocks › PYXS

Pyxis Oncology, Inc. (PYXS)

$1.44
▲ +2.13%
LAST CLOSE · NOV 17

Pyxis Oncology develops experimental cancer drugs, led by an antibody drug conjugate for head and neck squamous cell carcinoma. It last closed at $1.44 on Nov 17, up 2.13% on the day. The average 12-month price target from 4 analysts is $10.25 (+611.8% from the last close), with a high of $19.00 and a low of $7.00. Analyst consensus is Strong Buy, based on the latest ratings from 4 firms (4 buy, 0 hold, 0 sell).

AI Auto Pilots
Is PYXS in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$86.7M
EPS (diluted)
−$1.27
Free cash flow
−$70.9M
Valuation
Market cap
$172.2M
119.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$3.9M
At Sep 30
Shareholder equity
$41.3M
Shares outstanding
119.6M
At Nov 4
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2024: $16.1M$16.1MFY2024FY2025: $13.9M$13.9MFY2025

From PYXS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 4 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
4firms
4 Buy0 Hold0 Sell
Each firm's latest rating on PYXS in the past 90 days
Average 12-month target
$10.25
▲ 611.8% upside

Based on 4 analysts who set a price target on PYXS in the past 90 days. The average target is $10.25, with a high of $19.00 and a low of $7.00, compared with the last close of $1.44.

Low $7.00Avg $10.25High $19.00
Blue marker: last close $1.44
Highest target$19.00
Average target$10.25
Lowest target$7.00
Latest rating changes
RBC CapitalMaintained
Nov 6Buy$7
WedbushTarget lowered
Nov 6Buy$8 → $7
WedbushTarget raised
Sep 10Buy$6 → $8
HC Wainwright & Co.Target raised
Sep 10Buy$7 → $8
Wells FargoTarget raised
Sep 9Buy$12 → $19
DateFirmActionRatingPrice target
Nov 6RBC CapitalMaintainedBuy$7
Nov 6WedbushTarget loweredBuy$8 → $7
Sep 10WedbushTarget raisedBuy$6 → $8
Sep 10HC Wainwright & Co.Target raisedBuy$7 → $8
Sep 9Wells FargoTarget raisedBuy$12 → $19
Loading…

Technical Analysis

PYXS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 17% below its 20 day and 55% below its 50 day average. It is 50% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 31), near oversold. The nearest support is the Pivot S1 at $1.35, and the nearest resistance the Pivot R1 at $1.53.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 10.2%/day
Key levels
$5.5552 week high+285.4%
$2.60100 day average+80.6%
$2.2350 day average+54.9%
$2.16200 day average+50.0%
$1.79Swing high (Nov 9)+24.3%
$1.6820 day average+16.7%
$1.53Pivot R1+6.3%
$1.44Pivot+0.0%
$1.44Last close
$1.35Pivot S1−6.2%
$1.0352 week low−28.5%
Indicators
RSI (14)31.12Weak, oversold below 30Neutral
MACD-0.18Above its signal lineBullish
Stochastic9.8Near the bottom of its rangeOversold
ADX (14)37.0Trending down
Williams %R-85.9Oversold below −80, overbought above −20Oversold
CCI (20)-170.7Oversold below −100, overbought above 100Oversold
Rate of change−12.2%Change over 10 sessionsBearish
ATR (14)$0.15Typical daily range, 10.2% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PYXS

What happened before

See how PYXS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow PYXS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How PYXS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in PYXS in the last 90 days.

Loading…

See today’s whale options flow across the market →

PYXS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲64 buying vs 32 selling
  • ▲Held by funds +38.2 pts
  • ▲Funds holding +25
  • ▲Superinvestors: 3 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10176+32.9%
In funds' top 1042+100.0%
Held by funds66.7%28.6%+38.2 pts
New / increased38 / 269 / 24+93.9%
Reduced / sold out19 / 1324 / 10−5.9%
Put/call ratio0.000.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See PYXS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PYXS is in one of them and how their past PYXS trades turned out.

PYXS in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PYXS in an article yet. Here's the latest on the wider market.

About Pyxis Oncology

Pyxis Oncology is a cancer drug developer based in Boston, Massachusetts. Its lead product candidate, micvotabart pelidotin, is an experimental antibody drug conjugate that targets a protein found in the tissue surrounding tumors rather than on cancer cells themselves. The company is focused on head and neck squamous cell carcinoma and is testing the drug alone and together with Keytruda, an immunotherapy made by Merck. The drug is still in clinical testing and is not approved for sale, and it is aimed at patients with solid tumors.

Headquarters
Boston, MA